help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

First published online on February 26, 2008
First published online on February 27, 2008
Endocrine Reviews, doi:10.1210/er.2007-0037
A more recent version of this article appeared on May 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow RPHR Note
Right arrow All Versions of this Article:
29/3/303    most recent
Final Manuscript
Author Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haataja, L.
Right arrow Articles by Butler, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haataja, L.
Right arrow Articles by Butler, P. C.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Diabetes

Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis

Leena Haataja, Tatyana Gurlo, Chang J. Huang, and Peter C. Butler*

Larry Hillblom Islet Research Center, UCLA David Geffen School of Medicine, Los Angeles, California

* To whom correspondence should be addressed. E-mail: pbutler{at}mednet.ucla.edu,.

Type 2 diabetes (T2DM) is characterized by insulin resistance, defective insulin secretion, loss of {beta}-cell mass with increased {beta}-cell apoptosis and islet amyloid. The islet amyloid is derived from islet amyloid polypeptide (IAPP, amylin), a protein coexpressed and cosecreted with insulin by pancreatic {beta}-cells. In common with other amyloidogenic proteins, IAPP has the propensity to form membrane permeant toxic oligomers. Accumulating evidence suggests that these toxic oligomers, rather than the extracellular amyloid form of these proteins, are responsible for loss of neurons in neurodegenerative diseases. In this review, we discuss emerging evidence to suggest that formation of intracellular IAPP oligomers may contribute to {beta}-cell loss in T2DM. The accumulated evidence permits the amyloid hypothesis originally developed for neurodegenerative diseases to be reformulated as the toxic oligomer hypothesis. However, as in neurodegenerative diseases, it remains unclear exactly why amyloidogenic proteins form oligomers in vivo, what their exact structure is, and to what extent these oligomers play a primary or secondary role in the cytotoxicity in what are now often called unfolded protein diseases.


Key words: Type 2 diabetes • amyloid • IAPP • ER stress • oligomer




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
V. Poitout and R. P. Robertson
Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction
Endocr. Rev., May 1, 2008; 29(3): 351 - 366.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society